On Monday, Disc Medicine received an upgrade to its Relative Strength (RS) Rating, from 80 to 84.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique rating identifies share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating of at least 80 in the early stages of their moves.
Disc Medicine is now considered extended and out of buy range after clearing a 53.99 buy point in a third-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% earnings growth last quarter. Revenue gains came in at 0%.
Disc Medicine holds the No. 201 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
